dapsa

 

electronic Disease Activity Index for Psoriatic Arthritis

 

e

eDAPSA

 

Psoriasis arthritis assessment made easy and quick

 

 

 

 

ios dapsa

iOS version (Coming soon)
android dapsa

Android version (Coming soon)

web dapsa
Web version
pdf dapsa

Illustrative PDF (Coming soon)

pdf original dapsa

Original PDF (Coming soon)

 

What is the DAPSA? 

 

The Disease Activity index in PSoriatic Arthritis (DAPSA) is used to assess disease activity in patients with confirmed psoriatic arthritis (PsA). The score has become established, particularly in Europe, and is recommended by international experts as a measurement tool for assessing disease activity in PsA. The DAPSA index includes laboratory parameters, clinical aspects, and patient self-assessments. 

 

Validation

paper version: yes            digital version: no

How to use the eDAPSA

 

The DAPSA is based on four pillars: 

  1. number of joints with pressure pain (0 - 68)
  2. number of swollen joints (0 - 66)
  3. C-reactive protein (CRP) (mg/l)
  4. patient assessment of disease activity and pain.

 

To calculate the DAPSA or cDAPSA index, the values given above are added together in a sum score. 

dapsa screen

 

For the DAPSA:

 

 

Pressure painful joints (0 - 68) + swollen joints (0 - 66) + C-reactive protein (mg/l) + disease activity + pain.

 

To determine disease activity, the following values apply: 

  • 0 - 4 remission
  • 5 - 14 low disease activity
  • 15 - 28 medium disease activity
  • >28 high disease activity

 

 

For the cDAPSA:

 

 

Pressure painful joints (0 - 68) + swollen joints (0 - 66) + disease activity + pain.

 

To determine disease activity, the following values apply: 

  • 0 - 4 remission
  • 5 - 13 low disease activity
  • 14 - 27 medium disease activity
  • >27 high disease activity

 

The following versions of the eDAPSA are available

ios dapsa

iOS version (Coming soon)

android dapsa

Android version (Coming soon)

web dapsa
Web version
pdf dapsa

Illustrative PDF (Coming soon)

pdf original dapsa

Original PDF (Coming soon)

How was the eDAPSA developed? 

 

The DAPSA was developed by Professor Dr. Smolen and colleagues at the University Hospital in Vienna with the participation of international experts and validated based on clinical data.


To make the DAPSA applicable in clinical practice, a clinical version (cDAPSA) has been developed which can be used independently of inflammatory markers. In validation studies, a high agreement of the cDAPSA and DAPSA could be demonstrated.  

 

Features

 

use icon psa

USER-FRIENDLY
 

The DAPSA can now be filled out quickly and easily online. 

nature icon psa

SAVE PAPER
 

Take care of the environment! The simple DAPSA form can be filled out online and easily saved to your records, eliminating un-necessary printouts. 

patient icon psa

DOCUMENTATION
 

Document proriasis arthritis activity and save the results or forward them to your patient.

calculate icon psa

VALIDATED
 

The DAPSA is validated and has already been applied in many international studies. 

Our other tools

 

eeasi web
eflqa web
eiga web
eitch web
edlqi web
enappa web
epain web
epasi web
epbi web
epbik web
epbiw web
epgaforacne web
epgaforpsoriasis web
epsosat web
esaeasi web
esapasi web
escorad web
ewoundqol web
eerlangeratopiescore web

 

References

 

 Validation:

Schoels, M., Aletaha, D., Funovits, J., Kavanaugh, A., Baker, D., & Smolen, J. S. (2010). Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Annals of the rheumatic diseases, 69(8), 1441–1447. https://doi.org/10.1136/ard.2009.122259

 

Smolen, J. S., Schoels, M., & Aletaha, D. (2015). Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. Clinical and experimental rheumatology, 33(5 Suppl 93), S48–S50.

 

van Mens, Leonieke J. J.; van de Sande, Marleen G. H.; van Kuijk, Arno W. R.; Baeten, Dominique; Coates, Laura C. (2018): Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. In: Annals of the rheumatic diseases 77 (2), S. 251–257. DOI: 10.1136/annrheumdis-2017-211998

Our partners

 

uke 1
psonet
cles88irj0bil0gf5qbmkfcio clahx75m800wlq891u93kod65 cvderm
ddg2
bvd
cles91jyt00w4tqf506r77am2 imgpsh fullsize anim 1222